Report from the GSEV POST-ISEV2025 webinar: Single-EV insights and standardization imperatives

DOI: https://doi.org/10.47184/tev.2025.01.01

On 2 June 2025, the German Society for Extracellular Vesicles (GSEV) convened a webinar to distill and critically discuss major discoveries presented at the annual meeting of the International Society for EVs 2025 (ISEV2025) in Vienna. Early-career investigators summarized sessions on EV biogenesis, analytical technologies, and clinical translation, followed by a panel debate on methodological bottlenecks and future directions. The discussion affirmed that meaningful progress requires single-particle and single-recipient cell resolution, context-dependent purity criteria, and transparent reporting aligned with MISEV recommendations. This manuscript narrates the webinar’s content, synthesizes cross-cutting topics, and proposes actionable priorities for the EV field.

Keywords: Extracellular vesicles; Single-particle analysis; Standardization; Biogenesis; Lipidomics; Phase separation; Nanofluidic devices; Flow cytometry; Biomarker discovery; Clinical translation; EV corona; MISEV Guidelines

Introduction

The extracellular vesicle (EV) community continues to expand, yet the rapid proliferation of data complicates coherent interpretation and standardization [1–4]. Post-conference forums are, therefore, essential for consolidating insights and challenging assumptions. The ISEV2025 meeting showcased innovations in lipid-regulated biogenesis, phase-separation–driven cargo selection, single-vesicle multimodal analytics, clinical assay harmonization, and the growing interest in microbial EVs. Recognizing the need for immediate knowledge transfer, GSEV organized a follow-up webinar to interrogate these advances and to evaluate their translational potential. 

Moderated by Kerstin Menck, Eva Rohde, Eva-Maria Kraemer-Albers, Claudia Guenther, and Daniel Bachurski, the webinar assembled more than 90 registered participants. Three structured presentations covered basic EV biology, methodological innovation, and biomarker development. A concluding panel examined unresolved technical hurdles and training needs. The explicit objectives were (I) to clarify mechanistic concepts that emerged at the Vienna meeting, (II) to assess the robustness and reproducibility of new analytical platforms, and (III) to identify community-wide priorities for future EV research.

To be able to access the page content* you need a free MyTrillium account. Please log in with your MyTrillium credentials or register for free.

*Some contents are reserved for medical professionals due to legal regulations in accordance with the German Drug Advertising Act (Heilmittelwerbegesetz (HWG)).

Authors
Lisa Wessendorf*
Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany. Mildred Scheel School of Oncology Aachen Bonn Cologne Düsseldorf, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.
CECAD Center of Excellence on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany.
Fanni Annamária Boros*
Department of Molecular Neurology, University Hospital Erlangen,
Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany
Allegra Angenendt*
Department of Medicine A - Hematology, Hemostaseology, Oncology, Pulmonology
University of Münster, Münster, Germany
Claudia Günther#
Department of Medicine 1, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany;
Friedrich-Alexander-Universität Erlangen-Nürnberg Profile Center Immunomedicine, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany;
Deutsches Zentrum Immuntherapie, Universitätsklinikum Erlangen, Erlangen, Germany.
Daniel Bachurski# (Corresponding author:)
Department I of Internal Medicine, University Hospital Cologne Kerpener Str. 62, 50937 Cologne, Germany;
Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany; Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany;
Mildred Scheel School of Oncology Aachen Bonn Cologne Düsseldorf, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany; CECAD Center of Excellence on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany.
+49 221 478 84118

*Lisa Wessendorf, Fanni Annamária Boros, and Allegra Angenendt contributed equally as first authors.
#Claudia Günther and Daniel Bachurski contributed equally as last authors.
 

From the section